Fetoscopic Laser Ablation Therapy for Type II Vasa Previa
Ramen H Chmait1, Valerian Catanzarite2, Andrew H Chon3
1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, chmait@usc.edu.
Fetal Diagnosis and Therapy
|July 7, 2020
Summary
Fetoscopic laser ablation is a feasible treatment for type II vasa previa, offering successful vessel occlusion and improved perinatal outcomes. This minimally invasive approach can reduce hospital stays and the need for early delivery.
Area of Science:
- Maternal-Fetal Medicine
- Minimally Invasive Surgery
- Perinatal Outcomes
Background:
- Type II vasa previa poses risks of prolonged hospitalization, prematurity, and cesarean delivery with traditional management.
- Fetoscopic laser ablation presents a potential alternative to mitigate these complications.
Purpose of the Study:
- To evaluate the feasibility of fetoscopic laser ablation for type II vasa previa.
- To report the perinatal outcomes in patients treated with this technique.
Main Methods:
- Retrospective descriptive study of women with vasa previa treated with laser (2006-2019).
- Laser ablation offered after 31 gestational weeks post-2010.
- Analysis of procedural success, operative time, and perinatal data.
Main Results:
- 10 of 18 eligible patients with type II vasa previa underwent successful laser ablation.
- No perioperative complications were observed; most patients were managed as outpatients.
- Mean gestational age at delivery was 35.5 weeks; 5 vaginal deliveries occurred. A subset treated after 31 weeks had significantly later delivery (38.1 weeks) and all vaginal births.
Conclusions:
- Fetoscopic laser ablation is technically achievable for type II vasa previa.
- The procedure leads to favorable perinatal outcomes, including increased gestational age at delivery and a higher rate of vaginal births.
